Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18, with chronic genotype 1 HCV infection~* HCV treatment-naive~* HCV RNA \> 10,000 IU/mL at screening~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Presence of cirrhosis~* Coinfection with HIV or hepatitis B virus (HBV)~* Current or prior history of clinical hepatic decompensation~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 8 Week (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC for 8 weeks.
- LDV/SOF+RBV 8 Week (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC plus RBV for 8 weeks.
- LDV/SOF 12 Week (Type: EXPERIMENTAL): Participants will receive LDV/SOF FDC for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).